als
Washington (AFP) - Amylyx Pharmaceuticals announced Thursday it was withdrawing its approved treatment against the deadly neurodegenerative disease ALS after clinical data found no evidence the drug worked. In a statement, the US company said it would discontinue its market authorizations for Relyvrio/Albrioza, using the brand names of the medicine in the US and Canadian markets. "While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS and...
AFP
Washington (AFP) - A new treatment shows promise against the deadly neurodegenerative disease ALS, a study based on mice showed Tuesday. Amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease after the famous baseball player, devastates nerve cells in the brain and spinal cord. It affects about 30,000 Americans at any given time, causing progressive loss of motor and cognitive function. Most patients die within five years of their diagnosis. In the new research, published in the journal PLOS Biology, a team led by Jeffrey Agar of Northeastern University investigated a way to ta...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら